PHILADELPHIA, May 11 BioNanomatrix, Inc., a developer of breakthrough single-molecule genomic analysis technology, has elected David L. Barker, Ph.D., to its board of directors.
"Dr. Barker brings broad and in-depth scientific, business and corporate governance experience to the Board," said Tracy Warren, chairman of BioNanomatrix and a general partner of Battelle Ventures. "We are confident that his relevant industry knowledge and expertise will make a substantial contribution as we approach commercialization of our technology."
Dr. Barker said, "I believe that BioNanomatrix has game-changing technology that can detect and analyze long strands of DNA efficiently and effectively, and that this technology will contribute to the advancement of the life sciences and medicine in the coming years. I look forward to collaborating with the other board members and management."
Dr. Barker was vice president and chief scientific officer at Illumina, Inc., in San Diego, Calif., from 2000 through 2006. He served from 1998 to 2000 as vice president and chief science advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including vice president of research and business development at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham. He currently serves on the Boards of Directors of Cell Biosciences, Integrated Diagnostics, IntegenX Inc., and NextBio, and is a scientific advisor to Illumina, GenVault, Diagnostics for the Real World, Helixis, BiOptix, and DNA Direct. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, assistant professor at the University of Oregon and associate professor at Oregon State University. Dr. Barker holds a B.S. degree with honors in chemistry from the California Institute of Technology and a Ph.D. in biochemistry from Brandeis University.
BioNanomatrix is developing breakthrough nanotechnology-enabled genome analysis systems for applications in life science research, molecular diagnostics and personalized medicine. The company's platform technology permits users to image directly and analyze very long strands of DNA in real time at the single-molecule level, at both high resolution and very high throughputs. This technology has the potential to increase the utility of whole genome imaging and analysis for a wide range of research and diagnostic applications, providing fast, comprehensive and low-cost analysis of genomic, epigenomic and proteomic information. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pa., and is backed by Battelle Ventures, Ben Franklin Technology Partners of Southeastern Pennsylvania, KT Venture Group and other institutional and private investors. For more information, visit: www.bionanomatrix.com
Note: NANOANALYZER is a registered trademark of BioNanomatrix, Inc. The names of other companies, other entities, products and/or services mentioned herein may be the trademarks of their respective owners.
Media Contact: Tiberend Strategic Advisors, Inc. (212) 827-0020 Andrew Mielach [email protected]
or Tamara Bright [email protected]
SOURCE BioNanomatrix, Inc.